Drug Profile
Lung cancer vaccine - AVAX Technologies
Alternative Names: LungVaxLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator AVAX Technologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 15 Sep 2015 No reports on development identified - Phase-I/II for Non-small cell lung cancer in USA (Parenteral)
- 11 Apr 2008 The vaccine is still in phase I/II trials for Non-small lung cancer in the US
- 23 Jan 2006 Phase-I/II clinical trials in Non-small cell lung cancer in USA (Parenteral)